Patients with breast cancer with BRCA1 or BRCA2 who underwent BCT have a significantly higher risk of a second primary ipsilateral breast event that is almost exclusively a new primary breast cancer rather than a true recurrence [4-6]. This evidence concerns the gene BRCA2 and breast carcinoma.